Your Health, We Care
News, as an important means of information dissemination, covers a variety of fields and aspects, It is of great significance for transmitting information, establishing an image, and promoting development. Here, we will introduce in detail the three sections company news, medicine news, and research news.
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combination with glucocorticoids (steroids) to help manage androgen (testosterone-like ···【more】
Article source: Captain MedicineRelease date: 2024-12-17Recommended: 534
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel, demonstrated a high res···【more】
Article source: Captain MedicineRelease date: 2024-12-13Recommended: 407
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Lo···【more】
Article source: Captain MedicineRelease date: 2024-08-26Recommended: 533
On June 27, 2024, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use issued a favorable opinion recommending the approval of a marketing autho···【more】
Article source: Captain MedicineRelease date: 2024-08-19Recommended: 515
On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel, marking the first gene-engineered T-cell therapy approved for the treatment of solid tumors. Th···【more】
Article source: Captain MedicineRelease date: 2024-08-12Recommended: 458
On June 14, 2024, the US Food and Drug Administration (FDA) granted approval for blinatumomab (Blincyto, Amgen Inc.) to be used in the consolidation phase of multiphase chemotherap···【more】
Article source: Captain MedicineRelease date: 2024-08-07Recommended: 463
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. For patients with advanced or metastatic NSCLC, partic···【more】
Article source: Captain MedicineRelease date: 2024-08-05Recommended: 513
On June 26, 2024, the Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager,···【more】
Article source: Captain MedicineRelease date: 2024-08-01Recommended: 428
On June 27, 2024, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended a change to the marketing authorization terms for the dr···【more】
Article source: Captain MedicineRelease date: 2024-07-19Recommended: 552
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of Laos was in the spotlight for its outstanding performance. Their booth attracted a large audience and···【more】
Article source: Captain MedicineRelease date: 2024-07-09Recommended: 569
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Article source: Captain MedicineRelease date: 2024-07-09Recommended: 664
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appointed by the World Health Organization (WHO) and director of the Microbiology Laboratory of the Nationa···【more】
Article source: Captain MedicineRelease date: 2024-07-09Recommended: 566
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4242025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6072024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：702026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3922025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4072025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4002025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4542025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3712025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
